This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Neurology  • Neuro-ophthalmology  • Retinal/ Chorioretinal Disorders  • Drug Therapy  • Drug Therapy, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

An Evidence-Based Review

Meredith Saylor, BA; Linda K. McLoon, PhD; Andrew R. Harrison, MD; Michael S. Lee, MD

Arch Ophthalmol. 2009;127(4):402-406.

Objective  To review the available evidence for the neuroprotective qualities of brimonidine tartrate in optic nerve and retinal injury.

Methods  References for this study were obtained by running a search of the PubMed database using keywords brimonidine, neuroprotection, ischemic optic neuropathy, and 2-adrenergic agonists. References focusing on ocular hypertension were excluded.

Results  Forty-eight articles addressing 1 of 4 criteria for neuroprotection were included. The literature confirms that brimonidine therapy meets the first 3 criteria for neuroprotection: receptors on its target tissues, adequate penetration into the vitreous and retina at pharmacologic levels, and induction of intracellular changes that enhance neuronal resistance to insults or interrupt apoptosis in animal models. Brimonidine did not meet the final neuroprotective criterion of success in humans.

Conclusions  Experimental evidence has demonstrated that brimonidine is a potential neuroprotective agent. However, to date, clinical trials have failed to translate into similar efficacy in humans.

Author Affiliations: Departments of Ophthalmology (Ms Saylor and Drs McLoon, Harrison, and Lee), Otolaryngology (Dr Harrison), and Neurology and Neurosurgery (Dr Lee), University of Minnesota, Minneapolis.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?